Home / Research Library / REJUVENATION · Longevity-Pathway Research
REJUVENATION · Longevity-Pathway Research

The Most-Studied Longevity Peptides

2026-06-08 · ~3 min read · For laboratory and educational use only

All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.

The short version
  • This is a plain reference page that points lab researchers to the short peptides most often studied in aging research, such as Epithalon and GHK-Cu, with links to deeper write-ups.
  • The research is mostly early-stage, done in cell cultures and animals, not people, and studies vary in size and quality, so it shows what scientists are looking at, not proof that anything works in humans.
  • Some claims online are just personal stories, not controlled studies, and BioRegen does not make or back any of those claims; the honest read is that human evidence is thin or missing for most of these compounds.
  • None of these peptides is approved for use in people or animals; researcher attention is a measure of interest, not of effectiveness or any official approval.
  • BioRegen sells these materials strictly for laboratory and educational research, not for human or veterinary use, and nothing on the page is medical advice.

All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice. This page is a quick guide for lab researchers who want to know which peptides come up most often in published studies on aging and on cells that have stopped dividing. It does not cover any one peptide in full. Instead, it shows where researchers study each one, what they tend to measure, and where to find longer write-ups on this site.

Why "longevity peptides" attract research interest

"Longevity peptides" is a loose label that researchers use for a group of short peptides they have tested in studies of aging, of cells that stop dividing, of tissue repair, and of the support network that holds tissue together. These peptides are studied in lab dishes and in animals, not as approved treatments. When researchers run these studies, they tend to track a few things: how the protective caps on the ends of chromosomes change, which genes turn up or down, how many times skin cells can keep dividing, and the markers of connective tissue. Because these peptides are small and have a known, fixed structure, they are easy to work with as test tools in aging research. Researchers who want to compare several peptides at once often begin with an organized list, such as the research finder, and then narrow down to one peptide.

Epithalon: telomere and senescence research

Epithalon is a lab-made peptide built from four amino acids (Ala-Glu-Asp-Gly). It is one of the most-cited longevity peptides in lab research. Researchers study it to see how it relates to telomerase, an enzyme tied to the protective caps on chromosomes, and to how long human cells in a dish can keep dividing. In one often-cited dish study, researchers reported that treating human skin cells went along with longer telomere caps and with the cells dividing more times than dishes of cells usually can. Those are findings from a controlled dish experiment, not claims about what happens in people. For a deeper look at what the studies show, see the Epithalon research overview.

GHK-Cu: extracellular matrix and gene-expression research

GHK-Cu is a short peptide made of three amino acids (glycyl-L-histidyl-L-lysine) that binds copper. It is one of the most-studied peptides in research on connective tissue and on the support network that holds tissue together. Published studies have looked at how it relates to the buildup of collagen and other building-block molecules in animal wound models, and at broad changes in which genes turn on or off in cells grown in a dish. Researchers often use GHK-Cu as a benchmark when they compare peptides that act on this tissue support network. A closer look at these findings is in the GHK-Cu research overview. Researchers who plan bench work with the dried, powdered form also check the guide on how to reconstitute peptides for general lab handling notes.

Reading the literature critically

Most of the published work on longevity peptides is early-stage. It is done in lab dishes or in animals, and the studies differ in how many subjects they use and in how they are run. Researchers reading this work usually weigh how the study was designed, whether other studies got the same result, and whether what was measured really matters before they draw any conclusion. Some reports that float around online are just personal stories, not controlled data. Personal stories are not the same as controlled findings, and BioRegen does not make or back any claims based on them. For lab work, the peer-reviewed studies are still the right thing to rely on.

Frequently asked questions

What does "most-studied" mean in this context?

It means the peptides that show up most often in listed, peer-reviewed lab studies on aging-related questions. It is a measure of how much attention researchers give them, not of whether they work or are approved.

Are these peptides approved for any use?

No. None of the peptides named here is approved for use in people or animals. They are discussed only as subjects of lab and educational research.

Where can researchers compare multiple compounds?

The research finder lists the peptides and links to a write-up for each one, which is a handy place to start when comparing what the studies say.

Selected research references

Reference metadata sourced via PubMed.

For researchers building a reference library, the BioRegen research guide compiles handling and literature resources in one place; create a free account for 10% off your first order. Browse available laboratory materials in the rejuvenation research category.

All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.

Community & anecdotal, unverifiedWhat is being discussed right now. Longevity and anti-aging peptides have moved from niche corners into mainstream coverage, with outlets such as the New York Times, Bloomberg, Time, GQ, and Vogue running pieces on the broader "biohacking" and longevity-medicine boom, often framing these compounds as unapproved and under-studied in humans. Within biohacker and longevity communities, on longevity-focused podcasts, and among recovery and fitness circles, the names that come up most are epitalon (epithalon), GHK-Cu, and NAD+ along with its precursors NMN and NR, plus BPC-157 and TB-500 when conversation turns to tissue and injury recovery. NAD+ and NMN have the most public visibility, partly because consumer supplement brands like Tru Niagen (using Niagen, a branded form of nicotinamide riboside) and Elysium Health market NAD+ precursors as over-the-counter products, and because public figures associated with longevity messaging, including David Sinclair and Bryan Johnson's "Blueprint" project, are frequently cited in these discussions. GHK-Cu shows up heavily in skincare and "regenerative" cosmetic conversation, while epitalon is discussed mainly in longevity forums referencing older Russian research on the pineal peptide. Recurring themes in these venues include sourcing and purity worries around research-chemical suppliers, the FDA's 2023 reclassification actions affecting some peptides in compounding, injectable versus oral or topical formats, and frequent reminders that human evidence is thin or absent for most of these compounds. These are unverified anecdotal reports and current discussion, not controlled findings, and not BioRegen claims.

Explore the catalog

Browse Rejuvenation research materials, or see the full catalog.

Related research

More peptide research to explore

Explore the research line

Browse the BioRegen catalog, or grab the free reference guide · create a free account for 10% off your first order.